Sign In
Buy ABSI
$5.94
-0.410 (-6.46%)
At Close: Jun 03, 2026
World-renowned experts will guide the clinical development of ABS-201, a therapeutic antibody entering clinical trials for the treatment of androgenetic alopecia. World-renowned experts will guide the
Absci to Participate in Upcoming Investor Conferences
08:00am, Wednesday, 20'th Aug 2025
VANCOUVER, Wash. and NEW YORK, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, to
Absci Corporation (ABSI) Q2 2025 Earnings Call Transcript
12:25am, Wednesday, 13'th Aug 2025
Absci Corporation (NASDAQ:ABSI ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Alexander Khan - VP of Finance & Head of Investor Relations Christian Stegmann - Senio
Absci Corporation (ABSI) Reports Q2 Loss, Misses Revenue Estimates
06:21pm, Tuesday, 12'th Aug 2025
Absci Corporation (ABSI) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.22 per share a year ago.
Absci Reports Business Updates and Second Quarter 2025 Financial and Operating Results
04:05pm, Tuesday, 12'th Aug 2025
Strengthened balance sheet raising approximately $64 million in gross proceeds in July 2025; cash, cash equivalents, and short-term investments now sufficient to fund operations into the first half of
Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target
02:00am, Thursday, 07'th Aug 2025
BARCELONA, Spain and VANCOUVER, Wash., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Almirall (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI), a
Absci Corporation (ABSI) Expected to Beat Earnings Estimates: Should You Buy?
11:01am, Wednesday, 06'th Aug 2025
ABSCI CORP (ABSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025
04:05pm, Wednesday, 30'th Jul 2025
VANCOUVER, Wash. and NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design
Intel, Absci, AST SpaceMobile And Other Big Stocks Moving Lower In Friday's Pre-Market Session
08:34am, Friday, 25'th Jul 2025
U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Friday.
Absci Announces Pricing of Public Offering of Common Stock
08:45pm, Thursday, 24'th Jul 2025
VANCOUVER, Wash., July 24, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a clinical-stage biopharmaceutical company advancing potential breakthrough therapeutics designed wi
Absci Announces Proposed Public Offering of Common Stock
04:54pm, Thursday, 24'th Jul 2025
VANCOUVER, Wash., July 24, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a clinical-stage biopharmaceutical company advancing potential breakthrough therapeutics designed wi
Absci Appoints Biopharma Leader Mary Szela to Board of Directors
08:00am, Monday, 07'th Jul 2025
VANCOUVER, Wash., July 07, 2025 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced th
Absci to Participate in Upcoming Investor Conferences
08:00am, Tuesday, 20'th May 2025
VANCOUVER, Wash. and NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design,
Absci Corporation (ABSI) Q1 2025 Earnings Call Transcript
10:45pm, Tuesday, 13'th May 2025
Absci Corporation (NASDAQ:ABSI ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Alex Khan - VP, Finance and IR Sean McClain - Founder and Chief Executive Officer Zach Jo
Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates
06:30pm, Tuesday, 13'th May 2025
Absci Corporation (ABSI) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.22 per share a year ago.
